Drug Profile
TBC 3804
Latest Information Update: 24 Aug 2006
Price :
$50
*
At a glance
- Originator Encysive Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 23 Aug 2006 Discontinued - Preclinical for Inflammatory bowel disease in USA (unspecified route)
- 21 Dec 2004 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)